Lumivascular CTO Crossing Platform
Chronic Total Occlusions (CTO) in Coronary Vessels
Pre-clinicalActive
Key Facts
Indication
Chronic Total Occlusions (CTO) in Coronary Vessels
Phase
Pre-clinical
Status
Active
Company
About Avinger
Lumivascular (Avinger) is a private medical device innovator focused on transforming the treatment of coronary Chronic Total Occlusions (CTOs). Its core technology platform integrates real-time intravascular OCT imaging directly into a CTO-crossing catheter, aiming to provide unprecedented procedural accuracy while reducing reliance on fluoroscopy and contrast dye. Founded by seasoned medtech veterans, the company holds an extensive IP portfolio and is developing a platform intended to expand global access to complex CTO procedures. It appears to be in the late-stage development or early commercial phase, building on the founders' prior successful exits in the vascular device space.
View full company profile